Carfilzomib vs Ixazomib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Carfilzomib
Marketed by Amgen and partners
NCT01080391 · Phase 3 · completed
The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001).
Next expected readout: November 2026 · NCT04973605 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants (met)
Result source: NCT03158688
Ixazomib
Marketed by Takeda Pharmaceutical Company and partners
NCT01564537 · Phase 3 · completed
Participants were randomly assigned and quadruple-blinded to ixazomib plus lenalidomide and dexamethasone or matching placebo plus lenalidomide and dexamethasone, with 360 and 362 participants, respectively. The hard clinical primary endpoint of independently assessed progression-free survival was met: median progression-free survival was 20.6 versus 14.7 months, with a statistically significant difference between groups (p=0.012).
Next expected readout: March 2027 · NCT04068597 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47) (met)
Result source: NCT02312258
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Carfilzomib
- 26.3 vs 17.6vs Lenalidomide and Dexamethasone (Rd)NCT01080391
35 other results
- 35.6 vs 19.1 NCT03275285
- 41.7 vs 20.8 NCT03275285
- 18.7 vs 9.4 NCT01568866
- 22.3 vs 22.1 NCT01818752
- 11.2 NCT02412878
- 7.6 NCT02412878
- 3.7 vs 3.3 NCT01302392
- 5 NCT01903811
- 8 NCT01903811
- 15.3 NCT01677858
- 16.2 NCT01677858
- 3.7 NCT00511238
- 6.9 NCT00531284
- 1.8 NCT00531284
- 4.6 NCT00530816
- 8.2 NCT00530816
- 3.5 NCT00511238
- 12.9 NCT01677858
- 1.6 NCT00531284
- 21 NCT01677858
- 1.5 NCT00531284
- 1 NCT00531284
- 11.5 NCT00531284
- 2.9 NCT00531284
- 1.4 NCT00531284
- 4.6 NCT00531284
- 4.6 NCT00531284
- 1.8 NCT00531284
- 1.7 NCT00531284
- 3.8 NCT01775553
- 9.4 NCT00531284
- 13.6 NCT01677858
- 5.2 NCT00531284
- 1.8 NCT00531284
- 5.1 NCT00531284
- Ixazomib
- 20.6 vs 14.7+5.9 vs placeboNCT01564537
13 other results
- 35.3 vs 21.8 NCT01850524
- 26.5 vs 21.3 NCT02181413
- 17.4 vs 9.4 NCT02312258
- 18.7 vs 9.3 NCT01564537
- 10.1 vs 9.6 NCT02312258
- 21.3 NCT03748953
- 7.1 vs 4.8 NCT03170882
- 29.0 vs 29.0 NCT03416374
- 5.2 NCT02477215
- 22.1 NCT02917941
- 23.5 NCT02046070
- 23 NCT02046070
- 14.2 NCT02046070
OS, median
- Carfilzomib
- 10.2 vs 10+0.2 vs placeboNCT01302392
10 other results
- 48.3 vs 40.4 NCT01080391
- 47.6 vs 40 NCT01568866
- 50.8 vs 43.6 NCT03158688
- 15.2 NCT03029234
- 15.4 NCT00511238
- 15.6 NCT00511238
- 37.3 NCT00530816
- 45.6 NCT00530816
- 26 NCT01903811
- 22 NCT01903811
- Ixazomib
- 53.6 vs 51.6+2 vs placeboNCT01564537
6 other results
- 64.8 vs 69.5 NCT02312258
- 42.2 vs 29.4 NCT01564537
- 46.9 vs 30.9 NCT01564537
- 37.3 vs 48.3 NCT02312258
- 18.8 NCT03170882
- 23.2 NCT02477215
ORR
- Carfilzomib
- 82.5%bNCT03859427
56 other results
- 86.3% NCT03859427
- 35.8% NCT03029234
- 87.1% vs 66.7% NCT01080391
- 86.6% vs 82.9% NCT03275285
- 76.9% vs 62.6% NCT01568866
- 84.3% vs 74.7% NCT03158688
- 84.3% vs 78.8% NCT01818752
- 62.9% NCT02412878
- 40.8% NCT02412878
- 35.8% NCT03029234
- 35% NCT03029234
- 35% NCT03029234
- 74.2% NCT01677858
- 76.9% NCT01677858
- 15.4% NCT00531284
- 53% NCT00530816
- 16.1% NCT00530816
- 39.6% NCT00530816
- 88.1% NCT03412565
- 90.8% NCT03412565
- 84.8% NCT03412565
- 66.7% NCT01677858
- 93.3% NCT01677858
- 100% NCT01677858
- 33.3% NCT01677858
- 50% NCT00531284
- 38.5% NCT00531284
- 52.2% NCT00530816
- 17.1% NCT00530816
- 42.4% NCT00530816
- 97% NCT03412565
- 59.2% NCT03934684
- 53.8% NCT03934684
- 97.8% NCT01402284
- 36.4% NCT00531284
- 10% NCT00531284
- 0% NCT00531284
- 100% NCT00531284
- 37.5% NCT00531284
- 28.6% NCT00531284
- 50% NCT00531284
- 64.3% NCT00531284
- 25% NCT00721734
- 37.5% NCT00721734
- 50% NCT00531284
- 0% NCT00531284
- 33.3% NCT00531284
- 42.9% NCT00531284
- 33.3% NCT00531284
- 50% NCT00531284
- 0% NCT00531284
- 18.2% NCT00721734
- 27.3% NCT00721734
- 22.2% NCT00721734
- 100% NCT00531284
- 100% NCT00531284
- Ixazomib
- 78.3% vs 71.5%+6.8 vs placeboNCT01564537
10 other results
- 82% vs 80% NCT01850524
- 49% NCT02046070
- 63% NCT01864018
- 38% vs 41% NCT03170882
- 73.3% vs 71.8% NCT03416374
- 28% NCT02477215
- 84.4% NCT02917941
- 35% NCT02765854
- 35% NCT02765854
- 73% NCT02765854
VGPR or better
- Carfilzomib
- 72.6% vs 56.1%vs Carfilzomib + DexamethasoneNCT03275285
4 other results
- 71.6% NCT03412565
- 77.6% NCT03412565
- 80% NCT03412565
- 77.3% NCT03412565
- Ixazomib
- 48.1% vs 39%+9.1 vs placeboNCT01564537
2 other results
- 50% NCT02917941
- 42.2% vs 43.6% NCT03416374
MRD negativity
- Carfilzomib
- 18.3% vs 5.2%vs Carfilzomib and DexamethasoneNCT03158688
6 other results
- 18.9% NCT03859427
- 18.1% NCT03859427
- 44.4% NCT01402284
- 25.4% NCT03412565
- 21.5% NCT03412565
- 27.3% NCT03412565
- Ixazomib
- 59% vs 50%+9 vs placeboNCT01850524
3 other results
- 6% vs 3% NCT02312258
- 18% NCT02389517
- 31% NCT02389517
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
41 other shared endpoints and safety
Coverage. Carfilzomib: 45 of 45 rows · Ixazomib: 45 of 45 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Carfilzomib Rows use multiple source trials | Ixazomib Rows use multiple source trials |
|---|---|---|
| Complete responder rate · % of participants | 44.1% (n=179) vs 28.5% (n=123) Carfilzomib + Dexamethasonea,b NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 2 other source trials28.5% (n=312) vs 10.4% (n=154) Carfilzomib and Dexamethasone NCT03158688 · Phase 3 · combination 25.9% (n=478) vs 23.1% (n=477) Bortezomib, Melphalan, Prednisone NCT01818752 · Phase 3 · registry result, not featured evidence · combination | 26% (n=351) vs 14% (n=354) placeboa,b NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 |
| Duration of Response time to event · months | 28.6 vs 21.2 Lenalidomide and Dexamethasone (Rd) monthsb NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 4 other source trials7.2 vs 9.5 placebo months NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 NA vs NA Carfilzomib + Dexamethasone months NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 21.3 vs 10.4 Bortezomib months NCT01568866 · Phase 3 · combination NA vs 16.6 Carfilzomib and Dexamethasone months NCT03158688 · Phase 3 · combination | 26 vs 21.7 placebo monthsb NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 3 other source trials50.6 vs 37.5 placebo months NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 28.03 vs 15.31 Bortezomib + Lenalidomide + Dexamethasone months NCT03416374 · Phase 4 · registry result, not featured evidence · combination 14.8 vs 14.3 Pomalidomide months4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination |
| Duration of Response time to event · months No placebo or comparator arm | NA monthsc,d,b NCT03412565 · Phase 2 · combination show 2 more dosesNA months NCT03412565 · Phase 2 · combination NA months NCT03412565 · Phase 2 · combination | 22.92 months*c,d,b NCT02389517 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1.91 years as posted show 1 more dose23.76 months* NCT02389517 · Phase 2 · registry result, not featured evidence · converted to months from 1.98 years as posted |
| EORTC QLQ-C30 GHS absolute change · score | 65.1 vs 62.9 Bortezomib, Melphalan, Prednisone score @ 48wkd,e,b NCT01818752 · Phase 3 · registry result, not featured evidence · combination | -4.1 vs -1.7 placebo scored,e,b NCT02181413 · Phase 3 |
| EORTC QLQ-C30 GHS absolute change · score Cycle 10 | 67.98 vs 68.38 Carfilzomib and Dexamethasone score @ 36wkd,e Cycle 10 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 11 | 68.52 vs 67.42 Carfilzomib and Dexamethasone score @ 40wkd,e Cycle 11 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 12 | 67.47 vs 65.13 Carfilzomib and Dexamethasone score @ 44wkd,e Cycle 12 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 13 | 67 vs 67.49 Carfilzomib and Dexamethasone score @ 48wkd,e Cycle 13 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 14 | 66.12 vs 67.66 Carfilzomib and Dexamethasone score @ 52wkd,e Cycle 14 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 15 | 67.61 vs 69.34 Carfilzomib and Dexamethasone score @ 56wkd,e Cycle 15 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 16 | 66.41 vs 68.21 Carfilzomib and Dexamethasone score @ 60wkd,e Cycle 16 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 17 | 69.81 vs 69.44 Carfilzomib and Dexamethasone score @ 64wkd,e Cycle 17 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 18 | 66.29 vs 66.67 Carfilzomib and Dexamethasone score @ 68wkd,e Cycle 18 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 19 | 68 vs 69.68 Carfilzomib and Dexamethasone score @ 72wkd,e Cycle 19 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 2 | ||
| EORTC QLQ-C30 GHS absolute change · score Cycle 20 | 66.43 vs 71.04 Carfilzomib and Dexamethasone score @ 76wkd,e Cycle 20 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 21 | 67.42 vs 70.94 Carfilzomib and Dexamethasone score @ 80wkd,e Cycle 21 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 22 | 67.51 vs 68.52 Carfilzomib and Dexamethasone score @ 84wkd,e Cycle 22 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 23 | 66.67 vs 69.52 Carfilzomib and Dexamethasone score @ 88wkd,e Cycle 23 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 24 | ||
| EORTC QLQ-C30 GHS absolute change · score Cycle 25 | 66.21 vs 67.93 Carfilzomib and Dexamethasone score @ 96wkd,e Cycle 25 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 26 | 66.12 vs 70.71 Carfilzomib and Dexamethasone score @ 100wkd,e Cycle 26 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 3 | 63.1 vs 66.13 Carfilzomib and Dexamethasone score @ 8wkd,e Cycle 3 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 32 | 67.91 vs 66.67 Carfilzomib and Dexamethasone score @ 124wkf,d,g Cycle 32 NCT03158688 · Phase 3 · combination | 50 vs 50 Carfilzomib + Lenalidomide + Dexamethasone score @ 128wkf,d,g Cycle 32 NCT03416374 · Phase 4 · registry result, not featured evidence · combination |
| EORTC QLQ-C30 GHS absolute change · score Cycle 4 | 63.47 vs 66.67 Carfilzomib and Dexamethasone score @ 12wkd,e Cycle 4 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 5 | 64.45 vs 67.62 Carfilzomib and Dexamethasone score @ 16wkd,e Cycle 5 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 6 | 65.92 vs 68.06 Carfilzomib and Dexamethasone score @ 20wkd,e Cycle 6 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 7 | 65.73 vs 69.33 Carfilzomib and Dexamethasone score @ 24wkd,e Cycle 7 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 8 | 66.34 vs 69.44 Carfilzomib and Dexamethasone score @ 28wkd,e Cycle 8 NCT03158688 · Phase 3 · combination | |
| EORTC QLQ-C30 GHS absolute change · score Cycle 9 | 67.82 vs 65.72 Carfilzomib and Dexamethasone score @ 32wkd,e Cycle 9 NCT03158688 · Phase 3 · combination | |
| MRD Negative responder rate · % of participants No placebo or comparator arm | 25.4% (n=67)c,d,b NCT03412565 · Phase 2 · combination show 2 more doses27.3% (n=66) NCT03412565 · Phase 2 · combination 21.5% (n=65) NCT03412565 · Phase 2 · combination | 18% (n=11) @ 52wkc,d,b NCT02389517 · Phase 2 · registry result, not featured evidence · combination show 1 more dose31% (n=13) @ 52wk NCT02389517 · Phase 2 · registry result, not featured evidence |
| ORR responder rate · % of participants No placebo or comparator arm | 62.9% (n=240)20/70 mg/m² once weeklyc,h,d,b NCT02412878 · Phase 3 · combination show 1 more dose40.8% (n=238)20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination | 84.4% (n=32)4 mg + 25 mg + 40 mgh,d,b NCT02917941 · Phase 2 · registry result, not featured evidence · combination 3 other source trials49% (n=73) NCT02046070 · Phase 2 · registry result, not featured evidence · combination 63% (n=35) @ 48wk NCT01864018 · Phase 1/2 · registry result, not featured evidence · combination 28% (n=18)90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| ORR absolute value · percentage points No placebo or comparator arm | 16.7% (n=42)c,i,d,b NCT00511238 · Phase 2 show 1 more dose23.7% (n=257) NCT00511238 · Phase 2 · pooled | 48% (n=25)4 mgi,d,b NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination |
| Overall Survival time to event · months No placebo or comparator arm | NA months20/70 mg/m² once weeklyc,d,e,b NCT02412878 · Phase 3 · combination show 1 more doseNA months20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination | NA monthsd,e,b NCT03748953 · Phase 3 · registry result, not featured evidence 9 other source trialsNA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT02389517 · Phase 2 · registry result, not featured evidence · combination NA months NCT02389517 · Phase 2 · registry result, not featured evidence NA months4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 23.2 months90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 11.2 months20/70 mg/m² once weeklyc,d,e,b NCT02412878 · Phase 3 · combination show 1 more dose7.6 months20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination | 21.3 monthsd,e,b NCT03748953 · Phase 3 · registry result, not featured evidence 7 other source trialsNA months NCT02389517 · Phase 2 · registry result, not featured evidence · combination NA months NCT02389517 · Phase 2 · registry result, not featured evidence 22.05 months4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 23.5 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 14.2 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 23 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 5.2 months90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| PFS2 time to event · months | 47.18 vs 35.58 Carfilzomib + Dexamethasone monthsc,d,e,b NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 show 1 more dose47.18 vs 32.36 Carfilzomib + Dexamethasone months NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 | 84 vs 80.4 placebo monthsd,e,b NCT02181413 · Phase 3 1 other source trial51.3 vs 50.3 placebo months NCT02312258 · Phase 3 |
| Time to Progression time to event · months | NA vs 20.27 Carfilzomib + Dexamethasone monthsb NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 1 other source trialNA vs 17.5 Carfilzomib and Dexamethasone months NCT03158688 · Phase 3 · combination | 22.4 vs 17.6 placebo monthsb NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 4 other source trials45.8 vs 26.8 placebo months NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 26.6 vs 21.4 placebo months NCT02181413 · Phase 3 17.8 vs 9.6 placebo months NCT02312258 · Phase 3 8.4 vs 5.1 Pomalidomide months4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination |
| Time to Progression time to event · months No placebo or comparator arm | 9.4 months20/70 mg/m²c,j,k,b NCT00531284 · Phase 1/2 show 18 more doses1 months20/70 mg/m² NCT00531284 · Phase 1/2 1.6 months20/70 mg/m² NCT00531284 · Phase 1/2 NA months20/70 mg/m² NCT00531284 · Phase 1/2 6.9 months20/56 mg/m² NCT00531284 · Phase 1/2 11.5 months20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination NA months20/56 mg/m² NCT00531284 · Phase 1/2 1.6 months20/56 mg/m² NCT00531284 · Phase 1/2 NA months20/56 mg/m² NCT00531284 · Phase 1/2 4.6 months20/45 mg/m² NCT00531284 · Phase 1/2 4.6 months20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 1.6 months20/45 mg/m² NCT00531284 · Phase 1/2 1.6 months45 mg/m² NCT00531284 · Phase 1/2 5.2 months20/36 mg/m² NCT00531284 · Phase 1/2 1.8 months20/36 mg/m² Bolus NCT00531284 · Phase 1/2 1.7 months36 mg/m² NCT00531284 · Phase 1/2 1.8 months20/36 mg/m² Bolus NCT00531284 · Phase 1/2 1.8 months20/27 mg/m² Bolus NCT00531284 · Phase 1/2 5.1 months20 mg/m² Bolus NCT00531284 · Phase 1/2 | 21.3 monthsj,k,b NCT03748953 · Phase 3 · registry result, not featured evidence 4 other source trials22.57 months4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 30.9 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 16.8 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 32.2 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination |
| Time to Response time to event · months | 1.4 vs 1.5 Carfilzomib and Dexamethasone monthsd,b NCT03158688 · Phase 3 · combination | 1.02 vs 1.87 placebo monthsd,b NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 1 other source trial2 vs 1.1 Pomalidomide months4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination |
| Time to Response time to event · months No placebo or comparator arm | 2.6 monthsc,l,d,b NCT03934684 · Phase 4 · registry result, not featured evidence · combination show 1 more dose2.8 months NCT03934684 · Phase 4 · registry result, not featured evidence · combination | 2.1 monthsl,d,b NCT02046070 · Phase 2 · registry result, not featured evidence · combination |
| VGPR or Better responder rate · % of participants No placebo or comparator arm | 77.6% (n=67)c,d,b NCT03412565 · Phase 2 · combination show 3 more doses71.6% (n=67) NCT03412565 · Phase 2 · combination 77.3% (n=66) NCT03412565 · Phase 2 · combination 80% (n=65) NCT03412565 · Phase 2 · combination | 50% (n=32)4 mg + 25 mg + 40 mgd,b NCT02917941 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 1%m NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 68 more results0.6% NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 n/a: no completion milestone NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 —Carfilzomib NCT01568866 · Phase 3 89.7%Carfilzomib + DEX NCT01568866 · Phase 3 · combination 5.4%20/70 mg/m² once weekly NCT02412878 · Phase 3 · combination 8.8%20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination 67.3% NCT03158688 · Phase 3 · combination 71.6%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · combination 1.5%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · combination 77.3%Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · combination 78.5%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · combination 57.1%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/56 mg/m² NCT00531284 · Phase 1/2 100%20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 100%20/56 mg/m² NCT00531284 · Phase 1/2 100%20/56 mg/m² NCT00531284 · Phase 1/2 100%20/45 mg/m² NCT00531284 · Phase 1/2 85.7%20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 100%20/45 mg/m² NCT00531284 · Phase 1/2 100%45 mg/m² NCT00531284 · Phase 1/2 100%20/36 mg/m² NCT00531284 · Phase 1/2 85.7%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 100%36 mg/m² NCT00531284 · Phase 1/2 96.9%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 100%20/27 mg/m² Bolus NCT00531284 · Phase 1/2 100%20 mg/m² Bolus NCT00531284 · Phase 1/2 91.3%Carfilzomib (A0) NCT00511238 · Phase 2 85%Carfilzomib (A1) NCT00511238 · Phase 2 · pooled 58.6%20/27 mg/m² NCT00530816 · Phase 2 · pooled 74.3%20 mg/m² NCT00530816 · Phase 2 71.2%20 mg/m² NCT00530816 · Phase 2 92.3%Carfilzomib and Dexamethasone (Kd) NCT03934684 · Phase 4 · registry result, not featured evidence · combination 65.3%Carfilzomib, Lenalidomide and Dexa NCT03934684 · Phase 4 · registry result, not featured evidence · combination 16.2%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 78.6% NCT03029234 · Phase 3 · registry result, not featured evidence · combination 41.4% NCT01818752 · Phase 3 · registry result, not featured evidence · combination 0% NCT02969837 · Phase 2 · registry result, not featured evidence — NCT01402284 · Phase 2 · registry result, not featured evidence · combination 11.1%low-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 19.7%high-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT01775553 · Phase 2 · registry result, not featured evidence 20.5% NCT01351623 · Phase 2 · registry result, not featured evidence 75%Carfilzomib - Dialysis NCT00721734 · Phase 2 · registry result, not featured evidence 100%Carfilzomib - Mild RI NCT00721734 · Phase 2 · registry result, not featured evidence 80%Carfilzomib - Moderate RI NCT00721734 · Phase 2 · registry result, not featured evidence 66.7%Carfilzomib - Normal RF NCT00721734 · Phase 2 · registry result, not featured evidence 75%Carfilzomib - Severe RI NCT00721734 · Phase 2 · registry result, not featured evidence 0%56mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%45mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence —MTD: Carfilzomib NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 0%Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 0%Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 0%Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 2.8%Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 100%88 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 93.3%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 95.5%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 66.7%56 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 100%45 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence | 28.1%n NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 40 more results49.3%Ixazomib + LenDex NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3 18.5% NCT02181413 · Phase 3 n/a: no completion milestone NCT02312258 · Phase 3 — NCT03416374 · Phase 4 · registry result, not featured evidence · combination 0% NCT03748953 · Phase 3 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence 3%Arm A (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 2.8%Arm B (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 0%Arm C (Higher-dose Ixazomib Citrat NCT01415882 · Phase 2 · registry result, not featured evidence · combination 10.8%Arm D (Ixazomib Citrate, Dexametha NCT01415882 · Phase 2 · registry result, not featured evidence · combination 0%Arm E (Ixazomib Citrate, Cyclophos NCT01415882 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneIxazomib Combination Therapy NCT02924272 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneIxazomib Monotherapy NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy 30%Arm I (Ixazomib Citrate, Lenalidom NCT02389517 · Phase 2 · registry result, not featured evidence · combination 22.7%Arm II (Lenalidomide) NCT02389517 · Phase 2 · registry result, not featured evidence 0% NCT02412228 · Phase 2 · registry result, not featured evidence · combination 0%Arm A (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 0%Arm B (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 0%Arm C (Ixazomib, Dexamethasone, Le NCT02765854 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination 14.3% NCT02440464 · Phase 2 · registry result, not featured evidence 70.6%4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 33.3%4 mg NCT02168101 · Phase 2 · registry result, not featured evidence 66.7%3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 66.7%2.3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 88.9%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 89.7%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 82.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 95% NCT02499081 · Phase 2 · registry result, not featured evidence 0%4 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 0%3 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 0%90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 25%80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 25%70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —m NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 68 more results— NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 16.2% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 —Carfilzomib NCT01568866 · Phase 3 20.7%Carfilzomib + DEX NCT01568866 · Phase 3 · combination —20/70 mg/m² once weekly NCT02412878 · Phase 3 · combination —20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination — NCT03158688 · Phase 3 · combination —D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · combination —Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · combination —Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · combination —Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · combination 14.3%20/70 mg/m² NCT00531284 · Phase 1/2 0%20/70 mg/m² NCT00531284 · Phase 1/2 27.3%20/70 mg/m² NCT00531284 · Phase 1/2 33.3%20/56 mg/m² NCT00531284 · Phase 1/2 25%20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 20%20/56 mg/m² NCT00531284 · Phase 1/2 20.8%20/56 mg/m² NCT00531284 · Phase 1/2 0%20/45 mg/m² NCT00531284 · Phase 1/2 0%20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 50%20/45 mg/m² NCT00531284 · Phase 1/2 28.6%45 mg/m² NCT00531284 · Phase 1/2 0%20/36 mg/m² NCT00531284 · Phase 1/2 14.3%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 0%36 mg/m² NCT00531284 · Phase 1/2 10.8%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 25%20/27 mg/m² Bolus NCT00531284 · Phase 1/2 0%20 mg/m² Bolus NCT00531284 · Phase 1/2 28.3%Carfilzomib (A0) NCT00511238 · Phase 2 12.4%Carfilzomib (A1) NCT00511238 · Phase 2 · pooled 10%20/27 mg/m² NCT00530816 · Phase 2 · pooled 17.1%20 mg/m² NCT00530816 · Phase 2 22%20 mg/m² NCT00530816 · Phase 2 —Carfilzomib and Dexamethasone (Kd) NCT03934684 · Phase 4 · registry result, not featured evidence · combination —Carfilzomib, Lenalidomide and Dexa NCT03934684 · Phase 4 · registry result, not featured evidence · combination —20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination — NCT03029234 · Phase 3 · registry result, not featured evidence · combination 15.5% NCT01818752 · Phase 3 · registry result, not featured evidence · combination — NCT02969837 · Phase 2 · registry result, not featured evidence — NCT01402284 · Phase 2 · registry result, not featured evidence · combination —low-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination —high-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT01775553 · Phase 2 · registry result, not featured evidence 9.1% NCT01351623 · Phase 2 · registry result, not featured evidence 37.5%Carfilzomib - Dialysis NCT00721734 · Phase 2 · registry result, not featured evidence 8.3%Carfilzomib - Mild RI NCT00721734 · Phase 2 · registry result, not featured evidence 40%Carfilzomib - Moderate RI NCT00721734 · Phase 2 · registry result, not featured evidence 25%Carfilzomib - Normal RF NCT00721734 · Phase 2 · registry result, not featured evidence 0%Carfilzomib - Severe RI NCT00721734 · Phase 2 · registry result, not featured evidence 0%56mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%45mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence —MTD: Carfilzomib NCT02937571 · Phase 1/2 · registry result, not featured evidence —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 50%88 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 13.3%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 14.6%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 0%56 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 0%45 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence | —n NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 40 more results—Ixazomib + LenDex NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT02181413 · Phase 3 — NCT02312258 · Phase 3 — NCT03416374 · Phase 4 · registry result, not featured evidence · combination — NCT03748953 · Phase 3 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence —Arm A (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm B (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm C (Higher-dose Ixazomib Citrat NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm D (Ixazomib Citrate, Dexametha NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm E (Ixazomib Citrate, Cyclophos NCT01415882 · Phase 2 · registry result, not featured evidence · combination 0%Ixazomib Combination Therapy NCT02924272 · Phase 2 · registry result, not featured evidence · combination 13%Ixazomib Monotherapy NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy 15%Arm I (Ixazomib Citrate, Lenalidom NCT02389517 · Phase 2 · registry result, not featured evidence · combination 4.5%Arm II (Lenalidomide) NCT02389517 · Phase 2 · registry result, not featured evidence — NCT02412228 · Phase 2 · registry result, not featured evidence · combination —Arm A (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence —Arm B (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence —Arm C (Ixazomib, Dexamethasone, Le NCT02765854 · Phase 2 · registry result, not featured evidence · combination —4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination — NCT02440464 · Phase 2 · registry result, not featured evidence 32.4%4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination —4 mg NCT02168101 · Phase 2 · registry result, not featured evidence —3 mg NCT02168101 · Phase 2 · registry result, not featured evidence —2.3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 22.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 21.8%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 29.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination — NCT02499081 · Phase 2 · registry result, not featured evidence —4 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination —3 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 65.3%m NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 68 more results58.6% NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 72.9% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 58.7%Carfilzomib NCT01568866 · Phase 3 —Carfilzomib + DEX NCT01568866 · Phase 3 · combination 49.6%20/70 mg/m² once weekly NCT02412878 · Phase 3 · combination 43.4%20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination 68.5% NCT03158688 · Phase 3 · combination 44.8%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · combination 28.4%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · combination 33.3%Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · combination 56.9%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · combination 71.4%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/70 mg/m² NCT00531284 · Phase 1/2 54.5%20/70 mg/m² NCT00531284 · Phase 1/2 33.3%20/56 mg/m² NCT00531284 · Phase 1/2 37.5%20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 50%20/56 mg/m² NCT00531284 · Phase 1/2 45.8%20/56 mg/m² NCT00531284 · Phase 1/2 0%20/45 mg/m² NCT00531284 · Phase 1/2 35.7%20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 83.3%20/45 mg/m² NCT00531284 · Phase 1/2 57.1%45 mg/m² NCT00531284 · Phase 1/2 50%20/36 mg/m² NCT00531284 · Phase 1/2 57.1%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 33.3%36 mg/m² NCT00531284 · Phase 1/2 41.5%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 25%20/27 mg/m² Bolus NCT00531284 · Phase 1/2 33.3%20 mg/m² Bolus NCT00531284 · Phase 1/2 43.5%Carfilzomib (A0) NCT00511238 · Phase 2 47.4%Carfilzomib (A1) NCT00511238 · Phase 2 · pooled 38.6%20/27 mg/m² NCT00530816 · Phase 2 · pooled 34.3%20 mg/m² NCT00530816 · Phase 2 30.5%20 mg/m² NCT00530816 · Phase 2 38.5%Carfilzomib and Dexamethasone (Kd) NCT03934684 · Phase 4 · registry result, not featured evidence · combination 22.4%Carfilzomib, Lenalidomide and Dexa NCT03934684 · Phase 4 · registry result, not featured evidence · combination 37.7%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 32.5%20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 55.3% NCT03029234 · Phase 3 · registry result, not featured evidence · combination 49.6% NCT01818752 · Phase 3 · registry result, not featured evidence · combination 39.1% NCT02969837 · Phase 2 · registry result, not featured evidence 42.2% NCT01402284 · Phase 2 · registry result, not featured evidence · combination 39.4%low-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 47.4%high-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 23.1% NCT01775553 · Phase 2 · registry result, not featured evidence 63.6% NCT01351623 · Phase 2 · registry result, not featured evidence 100%Carfilzomib - Dialysis NCT00721734 · Phase 2 · registry result, not featured evidence 66.7%Carfilzomib - Mild RI NCT00721734 · Phase 2 · registry result, not featured evidence 100%Carfilzomib - Moderate RI NCT00721734 · Phase 2 · registry result, not featured evidence 41.7%Carfilzomib - Normal RF NCT00721734 · Phase 2 · registry result, not featured evidence 75%Carfilzomib - Severe RI NCT00721734 · Phase 2 · registry result, not featured evidence 33.3%56mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%45mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 65.2%MTD: Carfilzomib NCT02937571 · Phase 1/2 · registry result, not featured evidence —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 100%Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 66.7%Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 50%Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 45.7%Phase 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 16.7%88 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 26.7%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 39.3%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 0%56 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 33.3%45 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence | 56.8%n NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 40 more results—Ixazomib + LenDex NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 65.4%Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 73%Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3 27.4% NCT02181413 · Phase 3 23.7% NCT02312258 · Phase 3 37.8% NCT03416374 · Phase 4 · registry result, not featured evidence · combination 31.4% NCT03748953 · Phase 3 · registry result, not featured evidence 13.3% NCT02619682 · Phase 2 · registry result, not featured evidence 48.5%Arm A (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 31.4%Arm B (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 31.4%Arm C (Higher-dose Ixazomib Citrat NCT01415882 · Phase 2 · registry result, not featured evidence · combination 38.9%Arm D (Ixazomib Citrate, Dexametha NCT01415882 · Phase 2 · registry result, not featured evidence · combination 58.3%Arm E (Ixazomib Citrate, Cyclophos NCT01415882 · Phase 2 · registry result, not featured evidence · combination 44.4%Ixazomib Combination Therapy NCT02924272 · Phase 2 · registry result, not featured evidence · combination 52.2%Ixazomib Monotherapy NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy 25%Arm I (Ixazomib Citrate, Lenalidom NCT02389517 · Phase 2 · registry result, not featured evidence · combination 9.1%Arm II (Lenalidomide) NCT02389517 · Phase 2 · registry result, not featured evidence 8.3% NCT02412228 · Phase 2 · registry result, not featured evidence · combination 74.1%Arm A (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 45.5%Arm B (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 47.6%Arm C (Ixazomib, Dexamethasone, Le NCT02765854 · Phase 2 · registry result, not featured evidence · combination 55.6%4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination 52.4% NCT02440464 · Phase 2 · registry result, not featured evidence 35.3%4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 66.7%4 mg NCT02168101 · Phase 2 · registry result, not featured evidence 66.7%3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 0%2.3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 47.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 38.5%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 58.8%Ixazomib 4.0 mg + CYC 400 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 40% NCT02499081 · Phase 2 · registry result, not featured evidence 44%4 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 57.1%3 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 0%90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 42.1%80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 66.7%70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | m diarrhoea 43.4% anaemia 42.3% neutropenia 40.1% NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 62 more resultsanaemia 56.1% (placebo 47.1%) thrombocytopenia 36.9% (placebo 28.1%) pyrexia 26.1% (placebo 18.3%) NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 infusion related reaction 45.2% upper respiratory tract infection 41.2% diarrhoea 40.7% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 20/70 mg/m² once weekly anaemia 29% hypertension 24.4% pyrexia 23.1% NCT02412878 · Phase 3 · combination 20/27 mg/m² twice weekly anaemia 31.1% diarrhoea 21.7% hypertension 20.9% NCT02412878 · Phase 3 · combination peripheral sensory neuropathy 41.8% constipation 38.8% neutropenia 37.3% NCT03412565 · Phase 2 · combination 20/56 mg/m² + Dex fatigue 62.5% pyrexia 50% upper respiratory tract infection 50% NCT00531284 · Phase 1/2 · combination 20/45 mg/m² + Dex fatigue 64.3% cough 57.1% upper respiratory tract infection 50% NCT00531284 · Phase 1/2 · combination cough 42.3% anaemia 36.5% pyrexia 26.9% NCT03934684 · Phase 4 · registry result, not featured evidence · combination cough 26.5% diarrhoea 18.4% hypertension 18.4% NCT03934684 · Phase 4 · registry result, not featured evidence · combination 20/56 mg/m^2 once weekly neutropenia 29.1% anaemia 25.1% hypertension 21.5% NCT03859427 · Phase 3 · registry result, not featured evidence · combination 20/27 mg/m^2 twice weekly neutropenia 31.6% hypertension 24.2% anaemia 23.8% NCT03859427 · Phase 3 · registry result, not featured evidence · combination anaemia 61.8% platelet count decreased 48.8% upper respiratory tract infection 48.8% NCT03029234 · Phase 3 · registry result, not featured evidence · combination anaemia 35.4% pyrexia 35.4% nausea 35.2% NCT01818752 · Phase 3 · registry result, not featured evidence · combination fatigue 63% diarrhea 45.7% edema limbs 37% NCT02969837 · Phase 2 · registry result, not featured evidence lymphocyte count decreased 100% hypoalbuminemia 93.3% platelet count decreased 93.3% NCT01402284 · Phase 2 · registry result, not featured evidence · combination low-dose anemia 59.1% fatigue 59.1% platelet count decreased 42.4% NCT01903811 · Phase 2 · registry result, not featured evidence · combination high-dose anemia 66.7% fatigue 57.9% platelet count decreased 50.9% NCT01903811 · Phase 2 · registry result, not featured evidence · combination anemia 61.5% hypertension 53.8% platelet count decreased 53.8% NCT01775553 · Phase 2 · registry result, not featured evidence diarrhea 65.9% nausea 59.1% fatigue 54.5% NCT01351623 · Phase 2 · registry result, not featured evidence anaemia 62.5% thrombocytopenia 62.5% abdominal pain 50% NCT00721734 · Phase 2 · registry result, not featured evidence fatigue 75% anaemia 58.3% constipation 50% NCT00721734 · Phase 2 · registry result, not featured evidence anaemia 62.5% fatigue 50% dyspnoea 37.5% NCT00721734 · Phase 2 · registry result, not featured evidence 56mg/m2/Dose anxiety 33.3% hyperkalemia 33.3% hypertension 33.3% NCT02937571 · Phase 1/2 · registry result, not featured evidence 45mg/m2/Dose lymphocyte count decreased 66.7% skin infection 66.7% alanine aminotransferase increased 33.3% NCT02937571 · Phase 1/2 · registry result, not featured evidence lymphocyte count decreased 73.9% neutrophil count decreased 65.2% white blood cell decreased 60.9% NCT02937571 · Phase 1/2 · registry result, not featured evidence Dose Level 0 anemia 100% cd4 lymphocytes decreased 100% lymphocyte count decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination Dose Level 1 anemia 100% lymphocyte count decreased 100% neutrophil count decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination Dose Level 2 hypotension 100% lymphocyte count decreased 100% neutrophil count decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination Dose Level 3 anemia 100% platelet count decreased 100% white blood cell decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination platelet count decreased 100% lymphocyte count decreased 91.4% white blood cell decreased 91.4% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 88 mg/m² headache 66.7% fatigue 50% insomnia 50% NCT01677858 · Phase 1/2 · registry result, not featured evidence 70 mg/m² upper respiratory tract infection 80% diarrhoea 60% fatigue 60% NCT01677858 · Phase 1/2 · registry result, not featured evidence 70 mg/m² fatigue 52.8% nausea 40.4% insomnia 32.6% NCT01677858 · Phase 1/2 · registry result, not featured evidence 56 mg/m² anaemia 66.7% arthralgia 66.7% cardiac murmur 66.7% NCT01677858 · Phase 1/2 · registry result, not featured evidence 45 mg/m² fatigue 100% back pain 66.7% diarrhoea 66.7% NCT01677858 · Phase 1/2 · registry result, not featured evidence | n diarrhoea 51.5% (placebo 42.6%) constipation 34.6% (placebo 27.6%) anaemia 34.1% (placebo 29.2%) NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 32 more resultsdiarrhoea 77% (placebo 30%) oedema peripheral 55.5% (placebo 32.5%) constipation 48.2% (placebo 38.1%) NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 diarrhoea 41.7% (placebo 30%) oedema peripheral 40.5% (placebo 32.5%) constipation 36.2% (placebo 38.1%) NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 nausea 39.1% (placebo 15.4%) diarrhoea 34.3% (placebo 23.6%) arthralgia 26.6% (placebo 16.6%) NCT02181413 · Phase 3 nausea 27.9% (placebo 8.3%) diarrhoea 23.9% (placebo 12.7%) vomiting 23.9% (placebo 4%) NCT02312258 · Phase 3 diarrhoea 28.9% white blood cell count decreased 24.4% platelet count decreased 20% NCT03416374 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 40% (placebo 25%) diarrhoea 34.3% (placebo 25%) vomiting 25.7% (placebo 0%) NCT03748953 · Phase 3 · registry result, not featured evidence lymphocyte decreased 36.7% lymphocyte decreased 33.3% wbc decreased 33.3% NCT02619682 · Phase 2 · registry result, not featured evidence fatigue 87.9% nausea 84.8% platelet count decreased 81.8% NCT01415882 · Phase 2 · registry result, not featured evidence · combination fatigue 94.3% peripheral sensory neuropathy 88.6% platelet count decreased 74.3% NCT01415882 · Phase 2 · registry result, not featured evidence · combination fatigue 82.9% platelet count decreased 80% peripheral sensory neuropathy 77.1% NCT01415882 · Phase 2 · registry result, not featured evidence · combination fatigue 94.4% diarrhea 80.6% nausea 77.8% NCT01415882 · Phase 2 · registry result, not featured evidence · combination anemia 91.7% fatigue 91.7% lymphocyte count decreased 91.7% NCT01415882 · Phase 2 · registry result, not featured evidence · combination anaemia 33.3% upper respiratory tract infection 33.3% aspartate aminotransferase increased 22.2% NCT02924272 · Phase 2 · registry result, not featured evidence · combination hypertension 17.4% upper respiratory tract infection 13% ankle fracture 8.7% NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy diarrhea 95% fatigue 50% nausea 50% NCT02389517 · Phase 2 · registry result, not featured evidence · combination diarrhea 50% fatigue 40.9% upper respiratory infection 27.3% NCT02389517 · Phase 2 · registry result, not featured evidence platelet count decreased 91.7% lymphocyte count decreased 83.3% rash 83.3% NCT02412228 · Phase 2 · registry result, not featured evidence · combination pneumonia 33.3% colitis 22.2% upper respiratory infection 22.2% NCT02765854 · Phase 2 · registry result, not featured evidence conjunctivits 36.4% bone pain 18.2% pneumonia 18.2% NCT02765854 · Phase 2 · registry result, not featured evidence thrombocytopenia 42.9% neutropenia 19% pneumonia 19% NCT02765854 · Phase 2 · registry result, not featured evidence · combination 4 mg diarrhoea 38.9% peripheral sensory neuropathy 26.4% fatigue 23.6% NCT03170882 · Phase 2 · registry result, not featured evidence · combination pyrexia 14.3% (placebo 4.5%) myalgia 4.8% (placebo 0%) upper respiratory tract infection 4.8% (placebo 0%) NCT02440464 · Phase 2 · registry result, not featured evidence 4 mg + 25 mg + 40 mg constipation 50% upper respiratory tract infection 47.1% diarrhoea 41.2% NCT02917941 · Phase 2 · registry result, not featured evidence · combination 4 mg thrombocytopenia 100% anaemia 66.7% aspartate aminotransferase increased 66.7% NCT02168101 · Phase 2 · registry result, not featured evidence 3 mg gastritis 66.7% thrombocytopenia 66.7% abdominal pain 33.3% NCT02168101 · Phase 2 · registry result, not featured evidence 2.3 mg diarrhoea 100% dry eye 66.7% hypertension 66.7% NCT02168101 · Phase 2 · registry result, not featured evidence anaemia 30.6% diarrhoea 30.6% upper respiratory tract infection 25% NCT02046070 · Phase 2 · registry result, not featured evidence · combination diarrhoea 33.3% upper respiratory tract infection 26.9% anaemia 24.4% NCT02046070 · Phase 2 · registry result, not featured evidence · combination neutropenia 47.1% anaemia 32.4% nausea 29.4% NCT02046070 · Phase 2 · registry result, not featured evidence · combination hyperglycemia 85% hypoalbuminemia 80% fatigue 75% NCT02499081 · Phase 2 · registry result, not featured evidence 4 mg anemia 76% platelet count decreased 76% neutrophil count decreased 68% NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 3 mg anemia 85.7% lymphocyte count decreased 85.7% white blood cell decreased 85.7% NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation context differs: prior_therapy differs (experienced versus naive).
- bThe assessment timepoint is not available for both results.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dPopulation comparability has not been reviewed for both studies.
- eTreatment context has not been resolved for both arms.
- fTrial phases differ: Phase 3 versus Phase 4.
- gAssessment timepoints differ: 124 weeks versus 128 weeks.
- hTrial phases differ: Phase 3 versus Phase 2.
- iTrial phases differ: Phase 2 versus Phase 1/2.
- jTrial phases differ: Phase 1/2 versus Phase 3.
- kPopulation context differs: registered conditions differ.
- lTrial phases differ: Phase 4 versus Phase 2.
- mPopulation comparability has not been reviewed for 66 of these studies.
- nPopulation comparability has not been reviewed for 36 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Carfilzomib
show 1 more result
show 1 more result
show 3 more results
+ 72 further endpoints in the CSV export.
Ixazomib
show 1 more result
show 1 more result
show 1 more result
+ 104 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carfilzomib's landscape · Ixazomib's landscape